AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12568840 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 17beta‐E(2) administration from cycle day 20 until the next cycle day 2.
Number of subjects: 60
Study 12568840 — intervention group
Group type: COMPARATOR
Intervention: Control group (no E(2) administration).
Number of subjects: 60
Study 11689712 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) certoparin, self-administered for 3 months
Number of subjects: 118
Study 11689712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 9130335 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.9 g/kg)
Number of subjects: 12
Study 9130335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7881142 — intervention group
Group type: EXPERIMENTAL
Intervention: Drain placed through the epigastric trocar site (Group 1)
Number of subjects: 100
Study 7881142 — intervention group
Group type: COMPARATOR
Intervention: No drain placed (Group 2)
Number of subjects: 100
Study 3147477 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg zolpidem (ZOL)
Number of subjects: 6
Study 3147477 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg chlorpromazine (CPZ)
Number of subjects: 6
Study 3147477 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ZOL + CPZ
Number of subjects: 6
Study 3147477 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 6
Study 1771605 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (1 mg) via metered dose inhaler
Number of subjects: 20
Study 1771605 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (2 mg total: 1 mg from each inhaler) via both inhalers
Number of subjects: 20
Study 1771605 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (1 mg) via dry powder inhaler
Number of subjects: 20
Study 1771605 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline via dry powder inhaler
Number of subjects: 20
Study 1771605 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline via metered dose inhaler
Number of subjects: 20
Study 1771605 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline via both inhalers
Number of subjects: 20
Study 1771605 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (1 mg) via both inhalers
Number of subjects: 20
Study 1261205 — intervention group
Group type: EXPERIMENTAL
Intervention: Effervescent tablets
Number of subjects: 0
Study 1261205 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprietary effervescent health salt
Number of subjects: 0
Study 30541689 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth intervention for self-management of risk factors for cardiovascular disease and cognitive decline
Number of subjects: 343
Study 28931167 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention
Number of subjects: 412
Study 28931167 — intervention group
Group type: EXPERIMENTAL
Intervention: Social environmental intervention
Number of subjects: 412
Study 28931167 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical environmental intervention
Number of subjects: 412
Study 28931167 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 412
Study 26512848 — intervention group
Group type: EXPERIMENTAL
Intervention: One muscle surgery
Number of subjects: 31
Study 26512848 — intervention group
Group type: COMPARATOR
Intervention: Unilateral recess‐resect procedure
Number of subjects: 31
Study 23885993 — intervention group
Group type: EXPERIMENTAL
Intervention: High-lignan FLX (0.41 g lignans)
Number of subjects: 37
Study 23885993 — intervention group
Group type: COMPARATOR
Intervention: Regular FLX (0.15 g lignans)
Number of subjects: 37
Study 21157106 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 20mg
Number of subjects: 128
Study 21157106 — intervention group
Group type: COMPARATOR
Intervention: atorvastatin 40mg
Number of subjects: 128
Study 21157106 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 128
Study 19118120 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with losartan and lisinopril
Number of subjects: 1850
Study 19118120 — intervention group
Group type: COMPARATOR
Intervention: Losartan alone
Number of subjects: 1850
Study 17158129 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane 0.8%
Number of subjects: 32
Study 17158129 — intervention group
Group type: COMPARATOR
Intervention: Entonox (nitrous oxide 50%: oxygen 50%)
Number of subjects: 32
Study 15166558 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture (press needles at relaxation, tranquilizer point, and master cerebral point)
Number of subjects: 66
Study 15166558 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (press needles at shoulder, wrist, and extraneous auricular point)
Number of subjects: 66
Study 15166558 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Number of subjects: 66
Study 15166558 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 66
Study 11450179 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion, sertraline, and venlafaxine as adjuncts to mood stabilizers
Number of subjects: 500
Study 11450179 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 500
Study 9728431 — intervention group
Group type: EXPERIMENTAL
Intervention: PTFE grafts
Number of subjects: 131
Study 9728431 — intervention group
Group type: COMPARATOR
Intervention: DHV grafts
Number of subjects: 131
Study 7995315 — intervention group
Group type: EXPERIMENTAL
Intervention: Written information about the indications and limitations of benzodiazepines
Number of subjects: 128
Study 7995315 — intervention group
Group type: EXPERIMENTAL
Intervention: Both written and oral information
Number of subjects: 128
Study 7995315 — intervention group
Group type: COMPARATOR
Intervention: No information (control group)
Number of subjects: 128
Study 3056821 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotherapy
Number of subjects: 140
Study 3056821 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (Control)
Number of subjects: 140
Study 30325753 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant cisplatin-based chemotherapy
Number of subjects: 0
Study 30325753 — intervention group
Group type: EXPERIMENTAL
Intervention: Antigen-specific immunotherapy (cancer vaccination)
Number of subjects: 0
Study 30325753 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibition (ICI)
Number of subjects: 0
Study 30325753 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant administration of ICI
Number of subjects: 0
Study 28450350 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (20 mg/day) for 12 months
Number of subjects: 314
Study 28450350 — intervention group
Group type: EXPERIMENTAL
Intervention: On-statin cholesterol efflux capacity
Number of subjects: 314
Study 28450350 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HDL particle number
Number of subjects: 314
Study 28450350 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline cholesterol efflux capacity
Number of subjects: 314
Study 28450350 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HDL cholesterol
Number of subjects: 314
Study 28450350 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline apolipoprotein A-I
Number of subjects: 314
Study 28450350 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL particle number (on-statin)
Number of subjects: 314
Study 26111942 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 76
Study 26111942 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation (MM)
Number of subjects: 76
Study 26111942 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Rate Variability Biofeedback (HRV-BF)
Number of subjects: 76
Study 26111942 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 76
Study 23815547 — intervention group
Group type: EXPERIMENTAL
Intervention: DAFNE structured education programme
Number of subjects: 5000
Study 21485666 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigator guidance system
Number of subjects: 112
Study 21485666 — intervention group
Group type: COMPARATOR
Intervention: Standard post open-heart surgery care
Number of subjects: 112
Study 19223344 — intervention group
Group type: EXPERIMENTAL
Intervention: Purpose built shade sails installed in winter 2005 at full sun study sites
Number of subjects: 51
Study 19223344 — intervention group
Group type: COMPARATOR
Intervention: Control schools (no shade sails)
Number of subjects: 51
Study 17043189 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical calcipotriene
Number of subjects: 0
Study 17043189 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated solar radiation
Number of subjects: 0
Study 17043189 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 0
Study 12622605 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management program
Number of subjects: 0
Study 12622605 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 10934569 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (24.52 hours per week for one year, gradually reducing over 1 to 2 years)
Number of subjects: 15
Study 10934569 — intervention group
Group type: COMPARATOR
Intervention: Parent training (3 to 9 months)
Number of subjects: 15
Study 9013398 — intervention group
Group type: EXPERIMENTAL
Intervention: Velnacrine (10, 25, 50 and 75 mg t.i.d.)
Number of subjects: 735
Study 9013398 — intervention group
Group type: EXPERIMENTAL
Intervention: Velnacrine
Number of subjects: 735
Study 9013398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 735
Study 1424619 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone + Gemeprost
Number of subjects: 0
Study 1424619 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilapan + Gemeprost
Number of subjects: 0
Study 1424619 — intervention group
Group type: COMPARATOR
Intervention: Gemeprost alone (Control)
Number of subjects: 0
Study 3912621 — intervention group
Group type: EXPERIMENTAL
Intervention: CMFVP for 1 year (ER+ patients)
Number of subjects: 0
Study 3912621 — intervention group
Group type: COMPARATOR
Intervention: CMFVP for 2 years (ER- patients)
Number of subjects: 0
Study 3912621 — intervention group
Group type: EXPERIMENTAL
Intervention: CMFVP for 1 year and/or hormonal therapy (ER+ patients)
Number of subjects: 0
Study 3912621 — intervention group
Group type: COMPARATOR
Intervention: CMFVP for 1 or 2 years (ER- patients)
Number of subjects: 0
Study 30954261 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum DR7 (9 log cfu/d) for 12 weeks
Number of subjects: 109
Study 30954261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 29489066 — intervention group
Group type: EXPERIMENTAL
Intervention: OBE022 administered after a standardized breakfast on day 1 and in the fasted state from day 3 to day 9
Number of subjects: 23
Study 29489066 — intervention group
Group type: EXPERIMENTAL
Intervention: OBE022 and OBE002
Number of subjects: 23
Study 29489066 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized meals on days 1, 3, and 9
Number of subjects: 23
Study 29489066 — intervention group
Group type: EXPERIMENTAL
Intervention: Food effect on the QT interval
Number of subjects: 23
Study 29489066 — intervention group
Group type: EXPERIMENTAL
Intervention: Change from predose, premeal and change from premeal, postdose
Number of subjects: 23
Study 26709818 — intervention group
Group type: EXPERIMENTAL
Intervention: Volar locking plate
Number of subjects: 140
Study 26709818 — intervention group
Group type: COMPARATOR
Intervention: External fixation with optional addition of K-wires
Number of subjects: 140
Study 25315893 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.0% hydrogen peroxide (White Class with Calcium, FGM)
Number of subjects: 64
Study 25315893 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% hydrogen peroxide (White Class with Calcium, FGM)
Number of subjects: 64
Study 25315893 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% hydrogen peroxide (Oral B 3D White, Oral‐B)
Number of subjects: 64
Study 25315893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 24300266 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubating Laryngeal Mask Airway (ILMA)
Number of subjects: 120
Study 24300266 — intervention group
Group type: COMPARATOR
Intervention: Direct Laryngoscope (DLS)
Number of subjects: 120
Study 20223617 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient engagement intervention
Number of subjects: 79
Study 20223617 — intervention group
Group type: COMPARATOR
Intervention: Safety Group (contacts on a different topic)
Number of subjects: 79
Study 20223617 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 79
Study 18058653 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous propofol alone (group P)
Number of subjects: 91
Study 18058653 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous propofol with oral midazolam premedication (group M + P)
Number of subjects: 91
Study 15734615 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 8851
Study 15734615 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 8851
Study 12899316 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive suppression
Number of subjects: 2
Study 12899316 — intervention group
Group type: COMPARATOR
Intervention: Natural response
Number of subjects: 2
Study 12899316 — intervention group
Group type: COMPARATOR
Intervention: Cognitive reappraisal
Number of subjects: 2
Study 11910594 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (50 micrograms per 24 hours)
Number of subjects: 45
Study 11910594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 11910594 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol
Number of subjects: 45
Study 8560293 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic-based smoking cessation interventions, details on dosage and duration not available
Number of subjects: 0
Study 8560293 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored counseling based on smoker's degree of addiction and readiness to quit
Number of subjects: 0
Study 8560293 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based anti-tobacco programs
Number of subjects: 0
Study 8560293 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased taxation on cigarettes
Number of subjects: 0
Study 8560293 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing the number of smoke-free environments
Number of subjects: 0
Study 1723378 — intervention group
Group type: EXPERIMENTAL
Intervention: Colfosceril palmitate (Exosurf Neonatal)
Number of subjects: 0
Study 1723378 — intervention group
Group type: COMPARATOR
Intervention: Air placebo
Number of subjects: 0
Study 6771931 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg nitroglycerin perlingual application
Number of subjects: 92
Study 6771931 — intervention group
Group type: COMPARATOR
Intervention: 0.6 mg inhalatively given isoprenalin
Number of subjects: 92
Study 6771931 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 92
Study 31135809 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast in the Classroom Initiative
Number of subjects: 0
Study 31135809 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 28526225 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Continuous Exercise (MICE)
Number of subjects: 13
Study 28526225 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Exercise (HIIE)
Number of subjects: 13
Study 28526225 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Interval Exercise (MIIE)
Number of subjects: 13
Study 25922424 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week individual CBT plus 400 mg/day modafinil
Number of subjects: 65
Study 25922424 — intervention group
Group type: COMPARATOR
Intervention: 12-week individual CBT only
Number of subjects: 65
Study 25922424 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week individual CBT plus 400 mg/day modafinil (high adherent patients)
Number of subjects: 65
Study 22160607 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of a non-friend
Number of subjects: 0
Study 22160607 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of a friend in positions allowing easy reach for the object
Number of subjects: 0
Study 22160607 — intervention group
Group type: EXPERIMENTAL
Intervention: Speaking with 'I' pronoun
Number of subjects: 0
Study 21988268 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Concentric Group (ECG)
Number of subjects: 21
Study 21988268 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Eccentric Group (EEG)
Number of subjects: 21
Study 21988268 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 21
Study 18277886 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication therapy
Number of subjects: 30
Study 18277886 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole treatment
Number of subjects: 30
Study 18277886 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole maintenance therapy
Number of subjects: 30
Study 18277886 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori negative status
Number of subjects: 30
Study 18277886 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of cirrhosis
Number of subjects: 30
Study 17317931 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid exercise protocol
Number of subjects: 12
Study 17317931 — intervention group
Group type: COMPARATOR
Intervention: Conventional isometric electrical stimulation program
Number of subjects: 12
Study 14515063 — intervention group
Group type: EXPERIMENTAL
Intervention: M201V [corrected] CysLT2 receptor variant
Number of subjects: 100
Study 14515063 — intervention group
Group type: COMPARATOR
Intervention: Non-atopic individuals
Number of subjects: 100
Study 11193249 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous alendronate
Number of subjects: 140
Study 11193249 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical alendronate
Number of subjects: 140
Study 11193249 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical etidronate
Number of subjects: 140
Study 11193249 — intervention group
Group type: COMPARATOR
Intervention: Calcitriol
Number of subjects: 140
Study 1527228 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 57
Study 1527228 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 57
Study 1527228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 3887847 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 50
Study 3887847 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 50
Study 3887847 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril + Hydrochlorothiazide
Number of subjects: 50
Study 3887847 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol + Hydrochlorothiazide
Number of subjects: 50
Study 30506183 — intervention group
Group type: EXPERIMENTAL
Intervention: Local injection of botulinum toxin
Number of subjects: 58
Study 30506183 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy of pelvic floor muscles (including functional electrical stimulation and desensitization)
Number of subjects: 58
Study 29415699 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence-supporting app with daily treatment reminders and electronic monitor (EM) for Cal/BD cutaneous foam.
Number of subjects: 134
Study 29415699 — intervention group
Group type: COMPARATOR
Intervention: Cal/BD cutaneous foam and EM without the app (Control).
Number of subjects: 134
Study 29415699 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence-supporting app with daily treatment reminders and EM for Cal/BD cutaneous foam.
Number of subjects: 134
Study 27255755 — intervention group
Group type: EXPERIMENTAL
Intervention: N95 respirators
Number of subjects: 0
Study 27255755 — intervention group
Group type: COMPARATOR
Intervention: Medical masks
Number of subjects: 0
Study 24884340 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 47
Study 24884340 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term dynamic therapy
Number of subjects: 47
Study 24884340 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased activating affects (AA) within a session
Number of subjects: 47
Study 24884340 — intervention group
Group type: COMPARATOR
Intervention: Cognitive therapy and Short-term dynamic therapy
Number of subjects: 47
Study 22109352 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-delivered mixed aerobic and resistance exercise intervention
Number of subjects: 143
Study 22109352 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 143
Study 20199819 — intervention group
Group type: EXPERIMENTAL
Intervention: Approach direction from five directions
Number of subjects: 8
Study 20199819 — intervention group
Group type: EXPERIMENTAL
Intervention: Working height at six different heights
Number of subjects: 8
Study 18651155 — intervention group
Group type: EXPERIMENTAL
Intervention: PET-CT
Number of subjects: 111
Study 18651155 — intervention group
Group type: COMPARATOR
Intervention: PET
Number of subjects: 111
Study 18651155 — intervention group
Group type: EXPERIMENTAL
Intervention: Length-SUV index
Number of subjects: 111
Study 18651155 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined quantitative (length-SUV index) and qualitative (visual) analysis
Number of subjects: 111
Study 15741033 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular angle reduction forceps
Number of subjects: 46
Study 15741033 — intervention group
Group type: COMPARATOR
Intervention: Intermaxillary fixation (IMF)
Number of subjects: 46
Study 11940139 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser (80 mJ/pulse, 3 Hz)
Number of subjects: 30
Study 11940139 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentin Protector (polyurethane‐isocyanate 22.5%; methylenechloride 77.5%)
Number of subjects: 30
Study 11940139 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 30
Study 10803996 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative urinary bladder catheterization (with Foley)
Number of subjects: 261